Pharmaceuticals News and Research

RSS
ICER’s drug assessment program to provide trusted source of information about new drugs

ICER’s drug assessment program to provide trusted source of information about new drugs

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Expanded use for IntelliCap with further CE Mark for aspiration of fluids

Expanded use for IntelliCap with further CE Mark for aspiration of fluids

Compliance - Hear from CCO from Lundbeck, Daiichi Sankyo and Novartis

Compliance - Hear from CCO from Lundbeck, Daiichi Sankyo and Novartis

PAREXEL introduces next generation Perceptive MyTrials Analytics solution

PAREXEL introduces next generation Perceptive MyTrials Analytics solution

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

MetLife Foundation Awards for Medical Research presented at AAIC 2015

MetLife Foundation Awards for Medical Research presented at AAIC 2015

Patients' own genetically engineered immune cells show significant success against multiple myeloma

Patients' own genetically engineered immune cells show significant success against multiple myeloma

New technique holds promise for improving glycoprotein-based pharmaceuticals

New technique holds promise for improving glycoprotein-based pharmaceuticals

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

IAOCR announces pilot Clinical Operations Workforce Quality Accreditation at organizational level

IAOCR announces pilot Clinical Operations Workforce Quality Accreditation at organizational level

Valeant Pharmaceuticals enters into definitive agreement to acquire Amoun Pharmaceutical

Valeant Pharmaceuticals enters into definitive agreement to acquire Amoun Pharmaceutical

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

Researchers demonstrate new multispectral microscope to speed up drug discovery

Researchers demonstrate new multispectral microscope to speed up drug discovery

Natural supplement may improve quality of life for people who have celiac disease and gluten intolerance

Natural supplement may improve quality of life for people who have celiac disease and gluten intolerance

Novel cancer drug candidate developed in Singapore advances into clinical trials

Novel cancer drug candidate developed in Singapore advances into clinical trials

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.